The New England journal of medicine | 2019
Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
Abstract
The Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial, the results of which are reported in this issue of the Journal,1 involved patients with metastatic, castration-...